アジア太平洋地域の胃腸治療薬市場（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Gastrointestinal Therapeutics in Asia-Pacific Market – Introduction 11
2.1 Irritable Bowel Syndrome 11
2.1.1 Classification 11
2.1.2 Symptoms 11
2.1.3 Etiology 11
2.1.4 Pathophysiology 12
2.1.5 Diagnosis 12
2.1.6 Epidemiology 14
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Ulcerative Colitis 15
2.2.1 Classification 15
2.2.2 Symptoms 17
2.2.3 Etiology 17
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 18
2.2.6 Epidemiology 19
2.2.7 Prognosis 19
2.2.8 Treatment Options 19
2.3 Crohn’s Disease 21
2.3.1 Classification 21
2.3.2 Symptoms 22
2.3.3 Etiology 22
2.3.4 Pathophysiology 23
2.3.5 Diagnosis 23
2.3.6 Epidemiology 24
2.3.7 Prognosis 24
2.3.8 Treatment Options 25
3 Gastrointestinal Therapeutics in Asia-Pacific Market – Marketed Products (Global) 26
3.1 Irritable Bowel Syndrome 26
3.2 Ulcerative Colitis 26
3.3 Crohn’s Disease 26
3.4 Key Marketed Products 27
3.4.1 Amitiza 27
3.4.2 Humira 28
3.4.3 Remicade 29
3.4.4 Simponi 30
3.4.5 Cimzia 31
3.4.6 Tysabri 32
4 Gastrointestinal Therapeutics in Asia-Pacific Market – Pipeline Analysis 34
4.1 Irritable Bowel Syndrome 34
4.1.1 Overall Pipeline 34
4.1.2 Pipeline Analysis by Molecule Type 36
4.1.3 Pipeline Analysis by Mechanism of Action 37
4.2 Ulcerative Colitis Pipeline 39
4.2.1 Overall Pipeline 39
4.2.2 Pipeline Analysis by Molecule Type 41
4.2.3 Pipeline Analysis by Mechanism of Action 42
4.3 Crohn’s Disease Pipeline 44
4.3.1 Overall Pipeline 44
4.3.2 Pipeline Analysis by Molecule Type 46
4.3.3 Pipeline Analysis by Mechanism of Action 47
4.4 Promising Drug Candidates in the Pipeline 49
4.4.1 GSK-1605786 49
4.4.2 MLN0002 49
4.4.3 EMD-61753 49
5 Gastrointestinal Therapeutics in Asia-Pacific Market – Market Forecast to 2019 50
5.1 Asia-Pacific Markets 50
5.1.1 Treatment Usage Patterns 50
5.1.2 Annual Cost of Therapy 50
5.1.3 Market Size 50
5.2 Australia 52
5.2.1 Treatment Usage Patterns 52
5.2.2 Annual Cost of Therapy 52
5.2.3 Market Size 52
5.3 India 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 54
5.3.3 Market Size 54
5.4 China 56
5.4.1 Treatment Usage Patterns 56
5.4.2 Annual Cost of Therapy 56
5.4.3 Market Size 56
5.5 Japan 58
5.5.1 Treatment Usage Patterns 58
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 58
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 60
6 Gastrointestinal Therapeutics in Asia-Pacific Market – Deals and Strategic Consolidations (Global) 61
6.1 Deals Analysis 61
6.2 Major Co-Development Deals 63
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn’s Disease 64
6.3 Major Licensing Deals 65
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66
7 Gastrointestinal Therapeutics in Asia-Pacific Market – Appendix 67
7.1 Market Definitions 67
7.2 Abbreviations 67
7.3 Sources 69
7.4 All Pipeline Drugs by Phase 71
7.4.1 Discovery 71
7.4.2 Preclinical 71
7.4.3 IND/CTA-filed 72
7.4.4 Phase I 73
7.4.5 Phase II 74
7.4.6 Phase III 76
7.4.7 Pre-Registration 76
7.4.8 Undisclosed 77
7.5 Market Forecasts to 2019 77
7.5.1 Asia-Pacific Markets 77
7.5.2 Australia 78
7.5.3 India 79
7.5.4 China 80
7.5.5 Japan 81
7.6 Research Methodology 82
7.6.1 Coverage 82
7.6.2 Secondary Research 83
7.6.3 Primary Research 83
7.6.4 Therapeutic Landscape 83
7.6.5 Geographical Landscape 86
7.6.6 Pipeline Analysis 86
7.7 Expert Panel Validation 86
7.8 Contact Us 86
7.9 Disclaimer 86